Phase 4 N=50 Carbetocin on Myocardial Repolarization Dynamics in Obstetrics Study
Cardiac Arrythmias
Primary: Tp-e — 69.5; 74.7 milliseconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=36 A TQT Study of Effect of M2951 on Cardiac Repolarization
Healthy
Primary: Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Evobrutinib — -1.62; -2.28 milliseconds
Phase 1 N=22 Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block
Drug-induced QT Prolongation · Pharmacokinetics · Pharmacodynamics
Primary: Change in Placebo Corrected Change From Baseline QTc and J-Tpeakc Intervals on the ECG Measured in Milliseconds When Dofetilide is Administered With Mexiletine or…
N/A N=300 Electrophysiological Effects of Late PCI After MI
Cardiovascular Diseases · Heart Diseases · Myocardial Infarction
Primary: Short-termed Fractal Scaling Exponent (Alpha 1) — 0.01; -0.03 unit-less — p=0.34
Phase 1 N=60 CiPA Phase 1 ECG Biomarker Validation Study
Drug-induced QT Prolongation · Pharmacokinetics · Pharmacodynamics
Primary: Change From Baseline J-Tpeakc With "Balanced Ion Channel" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir) — -8.3; -7.8; -11.5; -10.9 ms
Phase 1 N=22 Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects
Drug-induced Surface ECG Changes
Primary: Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc — 6.5; 2.3; 32.1; 5.1 ms — p=<0.05
N/A N=32 T-Wave Alternans in Acute Myocardial Infarction: An Evaluation of the Time of Testing on Its Prognostic Accuracy
Myocardial Infarction · Arrhythmias
Primary: Evaluate the Diagnostic Accuracy of TWA in Predicting Arrhythmic Events, Cardiovascular Mortality, and Total Mortality in Patients With Acute MI
Phase 1 N=48 Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)
Anesthesia; Adverse Effect · Cardiac Arrhythmia
Primary: Change-from-baseline in QTc Interval — 2.1; 5.1; -0.1; 4.1 ms — p=<0.05
Phase 2 N=126 Post-Myocardial Infarction Remodeling Prevention Therapy
Acute Myocardial Infarction · Pacing Therapy · Cardiac Remodeling
Primary: Change in Left Ventricular End Diastolic Volume (LVEDV) — 16.4; 15.8 mL
Phase 2 N=39 Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
Solid Tumors
Primary: Change in QTcF (QT Corrected According to Fridericia's Formula) — 3.32; 1.76; 1.84; 1.32 ms (Milliseconds)
Phase 1 N=70 Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults
QT Intervals Changes · QTc Intervals Changes
Primary: Placebo-corrected Change From Baseline in QT Interval Corrected for Heart Rate Based on the Fridericia Method (QTcF) After Omecamtiv Mecarbil Dosing in Part B — -2.6…
N/A N=11 Intracardiac T-wave Alternans and Ischemia
Ischemia
Primary: Number of Subjects With Positive T Wave Studies During a Coronary Intervention — 0 participants
Phase 2 N=55 Cardiac Electrophysiological Study
Atrial Flutter
Primary: LAERP (Left Atrial Effective Refractory Period (ie, the Longest S1-S2 Interval That Fails to Result in Atrial Depolarisation)) — 11; 43; 55; 50 ms
Phase 1 N=26 QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors
Advanced Solid Tumor
Primary: Mean Time-matched, Baseline Corrected QTcF at Any Time Point Postdosing. — 2; 11 msec
Phase 1 N=48 Staccato Prochlorperazine Thorough QT/QTc
Cardiotoxicity
Primary: Maximum Effect of Inhaled Prochlorperazine on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 5.493; 5.229 milliseconds
Phase 2 N=51 Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
Metastatic Breast Cancer
Primary: Change From Baseline in Mean Duration of the QTc Interval — 1.2; -1.0; -4.0; -0.1 milliseconds
Phase 1 N=67 Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization
Epilepsy
Primary: QTcI - QT Interval Individually Corrected for Heart Rate - Day 5 — -8.05; -6.15; -2.77; -4.39 msec
N/A N=195 Home Telemonitoring In Patients After Myocardial Infarction
Myocardial Infarction · Heart Attack
Primary: Emergency Room Visits — 40; 33 Emergency Room Visits
N/A N=9 T-wave Alternans and Intrathoracic Impedance Measurements
Congestive Heart Failure · Arrhythmias
Primary: Number of Positive Twave Studies and Concurrent Positive Optivol Measurement — 1; 1; 2; 5 participants
Phase 2 N=25 Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
Long QT Syndrome
Primary: Change in QTc Duration at 2 Months — 503; 497 miliseconds — p=0.7958
Phase 1 N=48 Cardiac Safety Evaluation of P03277
Healthy Volunteers
Primary: Change-from-baseline Mean Effect of P03277 on QT Interval Expressed as QTc According to Fridericia's Formula (∆QTcF) — 0.97; 5.05; 0.24; -0.11 milliseconds
N/A N=336 Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
Ischemic Heart Disease · Coronary Artery Disease · Ischemic Reperfusion Injury
Primary: Myeloperoxidase — 184.3; 66.5; 144.71 g/L
Phase 1 N=38 A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors
Solid Tumor
Primary: Time-matched Mean Change From Baseline in Corrected QT Intervals Based on the Fridericia's Correction Fomulation (QTcF) — 3.9; 3.5; 1.6; -0.3 millisecond (msec)
N/A N=35 Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
Long QT Syndrome · Cardiac Repolarization
Primary: QTc Response to Exercise on Versus Off Beta-blocker. — 320; 317; 317; 315 ms
Phase 2 N=300 Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
Reperfusion Injury · STEMI
Primary: Area Under the Curve (AUC) of Serum Creatine Kinase Isoenzyme Type Muscle-brain (CK-MB) — 6582.0; 6738.3; 5252.2; 5471.9 ng*hr/mL
Phase 4 N=81 Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging
Myocardial Perfusion Imaging · Myocardial Ischemia
Primary: Exercise-induced Perfusion Defect Size (PDS) Following Ranolazine and Placebo Treatment — 21.54; 20.87 percentage of myocardium — p=0.29
N/A N=242 Assessing Microvascular Resistance Via IMR To Predict Cumulative Outcome in STEMI Patients Undergoing Primary PCI
Multi Vessel Coronary Artery Disease · STEMI
Primary: Composite of: Cardiovascular Death*, Re-myocardial Infarct, Re-hospitalization for Heart Failure (HF) and Congestive Heart Failure (CHF), Resuscitation or ICD…
Phase 3 N=911 IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.
Angina, Unstable · Cardiovascular Diseases · Heart Diseases
Primary: Progression of Acute Coronary Syndrome to Myocardial Infarction — 200; 242 participants — p=0.28
Phase 1 N=72 A Study of LY2484595 on the Electrical Activity of the Heart
Healthy Volunteers
Primary: Change From Baseline to Day 10 in QT Interval Corrected for Heart Rate (QTc) for LY2484595 Versus Placebo — -2.7; -4.6; -2.0; -1.1 milliseconds (msec)
N/A N=63 Extracellular Matrix Marker of Arrhythmia Risk (EMMA)
Myocardiopathies · Ischemia, Myocardial · Arrythmia
Primary: MMP-2 — 173493.4; 139012.4 pg/ml